These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29700899)

  • 21. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
    Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
    J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic intravenous pamidronate for an infant with osteogenesis imperfecta type II.
    Fukahori K; Nirei J; Yamawaki K; Nagasaki K
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37188488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biphosphonates and osteogenesis imperfecta in children].
    Gandon-Laloum S
    Arch Pediatr; 2009 Jul; 16(7):1085-9. PubMed ID: 19423303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteogenesis imperfecta and intravenous pamidronate.
    Banerjee I; Shortland GJ; Evans WD; Gregory JW
    Arch Dis Child; 2002 Dec; 87(6):562-3. PubMed ID: 12456578
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E; Jorulf H; Söderhäll S
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.
    Lin CH; Chien YH; Peng SF; Tsai WY; Tung YC; Lee CT; Chien CC; Hwu WL; Lee NC
    Pediatr Neonatol; 2014 Aug; 55(4):306-11. PubMed ID: 24486247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
    Choi JH; Shin YL; Yoo HW
    J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
    Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
    J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brainstem and cerebellar hypoplasia associated with osteogenesis imperfecta type-5.
    Syamlal S; Shine S; Kunju M
    J Postgrad Med; 2006; 52(2):152-3. PubMed ID: 16679688
    [No Abstract]   [Full Text] [Related]  

  • 30. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome.
    Di Iorgi N; Maghnie M
    J Pediatr; 2006 Nov; 149(5):734. PubMed ID: 17095368
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The first case of Bruck syndrome associated with gastroschisis.
    Afşarlar ÇE; Peltek-Kendirci HN; Erdoğan D; Özgüner İF; Çavuşoğlu YH; Karaman A; Çetinkaya S
    Turk J Pediatr; 2013; 55(6):651-4. PubMed ID: 24577988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta.
    Adiyaman P; Ocal G; Berberoğlu M; Evliyaoğlu O; Aycan Z; Cetinkaya E
    Turk J Pediatr; 2004; 46(4):322-8. PubMed ID: 15641265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of osteogenesis imperfecta: who, why, what?
    Glorieux FH
    Horm Res; 2007; 68 Suppl 5():8-11. PubMed ID: 18174695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of intravenous Zolidronic acid in the treatment of pediatric osteogenesis imperfecta: a systematic review.
    Mahmoud I; Bouden S; Sahli M; Rouached L; Ben Tekaya A; Tekaya R; Saidane O; Abdelmoula L
    J Pediatr Orthop B; 2024 May; 33(3):283-289. PubMed ID: 37339526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E; Chlebna-Sokół D
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.